

## DAFTAR PUSTAKA

- Akbar TIS, Riyanti EY, Khairunnisa K, et al. 2023. Frekuensi Transfusi Darah Tidak Memiliki Hubungan Signifikan dengan Inkompatibilitas Transfusi Darah pada Pasien Thalassemia. *Journal Of The Indonesian Medical Association* 73: 183-90
- Aliviameita A. 2020. Buku Ajar Mata Kuliah Imunohematologi. *Umsida Press*: 1-148
- Alves VM, Martins PRJ, Soares S, et al. 2012. Alloimmunization screening after transfusion of red blood cells in a prospective study. *Revista brasileira de hematologia e hemoterapia* 34: 206-11
- Amalia A, Hafy Z, Liana P. 2021. Perbandingan Proporsi Antibodi Iregular pada Pasien Multitransfusi dan Pasien Non Multitransfusi di UTD RSUP Dr. Mohammad Hoesin Palembang: Comparison of the Proportion of Iregular Antibodies in Multitransfusion and Non Multitransfusion Patients at UTD RSUP Dr. Mohammad Hoesin Palembang. *Jurnal Surya Medika (JSM)* 7: 9-14
- Andriastuti M, Yuniar I, Indawati W, et al. Current Evidences in Pediatric Emergencies Management.
- Arthur CM, Stowell SR. 2023. The development and consequences of red blood cell alloimmunization. *Annual Review of Pathology: Mechanisms of Disease* 18: 537-64
- Budhiaty T. 2013. Rasio prevalensi alloantibodi pada pasien transfusi berulang dibanding tidak berulang. Universitas Gadjah Mada
- Chidtrakoon S, Jeumjanya N, Intharanut K, et al. 2020. Analysis of pretransfusion testing events occurring in patients at Thammasat University Hospital. *J Hematol Transfus Med* 30: 345-51
- Chuang M-T, Chang C-H. 2022. Hemolytic disease of the fetus and newborn caused by irregular antibody: a mortality case report and case series during the past 15 years in NCKUH. *Taiwanese Journal of Obstetrics and Gynecology* 61: 896-9
- Davari K, Soltanpour MS. 2016. Study of alloimmunization and autoimmunization in Iranian  $\beta$ -thalassemia major patients. *Asian journal of transfusion science* 10: 88
- De Winter DP, Hulzebos C, Van 't Oever RM, et al. 2023. History and current standard of postnatal management in hemolytic disease of the fetus and newborn. *European Journal of Pediatrics* 182: 489-500

- Françoise NS, Justin EZG, Bernard CT, et al. 2021. Prevalence of irregular antibodies in blood donors at Yaoundé Central Hospital, Cameroun. *The Journal of Medical Research* 7: 172-4
- Garg N, Sharma T, Singh B. 2014. Prevalence of irregular red blood cell antibodies among healthy blood donors in Delhi population. *Transfusion and Apheresis Science* 50: 415-7
- Gayathri A, Gupta D. 2020. Case series investigation on the Lewis system antibodies encountered during a routine screening in a tertiary care hospital-based blood center. *Asian Journal of Transfusion Science* 14: 54
- Ghasemi A, Abbasian S, Ghaffari K, et al. 2016. Prevalence of alloantibodies and autoantibodies in transfusion dependent thalassemia patients. *Iranian Journal of Blood and Cancer* 8: 80-5
- Handa A, Kukar N, Maharishi RN, et al. 2020. Analysis of red cell alloimmunization in multi transfused patients at a Tertiary care teaching hospital. *Journal of family medicine and primary care* 9: 2907
- Kalfa TA. 2016. Warm antibody autoimmune hemolytic anemia. *Hematology 2014, the American Society of Hematology Education Program Book* 2016: 690-7
- Kesehatan K. 2015. Standar Pelayanan Transfusi Darah. 91
- Koochakzadeh L, Kajiyazdi M, Khoshhal F, et al. 2023. Prevalence of Alloantibodies in Thalassemia Patients and Its Relationship With Age, Gender and Blood Group. *Acta Medica Iranica*
- Li H-Y, Guo K. 2022. Blood group testing. *Frontiers in Medicine* 9: 827619
- Li W, Ying L, Wen-juan L. 2020. Screening Results and Risk Factors Analysis of Irregular Antibodies in 8 775 Patients Receiving Blood Transfusions. *Journal of Clinical Transfusion and Laboratory Medicine* 22: 480
- Liang Y-L, Shi Y, Su Y-Q, et al. 2023. Maternal Cold-Reacting Immunoglobulin G Anti-M of MNS Blood Group System Causing Hemolytic Disease of the Fetus. *Iranian Journal of Immunology* 20: 129-34
- Liu J, Wang S, Sha D, et al. 2019. Effects of cooperative blood transfusion and homologous blood transfusion on the production of red blood cell irregular antibodies in obstetric patients. *Experimental and Therapeutic Medicine* 17: 3477-82
- Mahardika T. 2022. *Gambaran Hasil Uji Silang Serasi (Crossmatch) Pada Sampel Kantong Darah di Unit Transfusi Darah Rumah Sakit (UTDRS) Dr. H. Abdul Moeloek. Poltekkes Tanjungkarang*

- Makroo RN, Arora B, Bhatia A, et al. 2014. Clinical significance of antibody specificities to M, N and Lewis blood group system. *Asian journal of transfusion science* 8: 96
- Ningrum NR, Ritchie NK, Syafitri R. 2018. Skrining Antibodi Dan Identifikasi Antibodi Pada Pasien Transfusi Di Laboratorium Rujukan Unit Transfusi Darah Pmi Dki Jakarta. *Pros Pertem Ilm Nas Penelit dan Pengabdi Masy PINLITAMAS* 1: 589-96
- O'Brien S, Lea RA, Jadhao S, et al. 2023. Genetic Characterization of Blood Group Antigens for Polynesian Heritage Norfolk Island Residents. *Genes* 14: 1740
- Okoroiwu HU, Okafor IM. 2018. Demographic characteristics of blood and blood components transfusion recipients and pattern of blood utilization in a tertiary health institution in southern Nigeria. *BMC hematology* 18: 1-6
- Purwati D, Rofinda ZD, Husni H. 2020. Karakteristik Pasien Transfusi Darah dengan Inkompatibilitas Crossmatch di UTD RSUP DR. M. Djamil Padang. *Jurnal Kesehatan Andalas* 9: 308-12
- Redman M, Regan F, Contreras M. 1996. A Prospective Study of the Incidence of Red Cell Allo-Immune following Transfusion. *Vox Sanguinis* 71: 216-20
- Rianti p, mardiyah zr, solihin dd. 2023. Diversity of ABO blood groups, ethnic groups, and medical histories of university students in Indonesia. *Jurnal Natural* 23: 174-84
- Sadeghian M, Fatourehchi A, Lesanpezeski M, et al. 2013. Prevalence of anemia and correlated factors in the reproductive age women in rural areas of tabas. *Journal of family & reproductive health* 7: 139
- Siegel DL. 2001. Pretransfusion compatibility testing. In *Handbook of Transfusion medicine*, pp. 107-14: Elsevier
- Singh B, Chaudhary R, Elhence P, et al. 2022. A case report on non-D HDFN: Highlighting the role of antibody screening in RhD positive antenatal women. *Asian Journal of Transfusion Science* 16: 121
- Sood R, Makroo R, Riana V, et al. 2013. Detection of alloimmunization to ensure safer transfusion practice. *Asian journal of transfusion science* 7: 135
- Tarek me-g, efbtm rm, faten mm, et al. 2018. Prevalence of red cell blood group antigens among Egyptian population in comparison with other ethnic groups. *The Medical Journal of Cairo University* 86: 989-94
- Thakral B, Saluja K, Sharma RR, et al. 2008. Red cell alloimmunization in a transfused patient population: a study from a tertiary care hospital in north India. *Hematology* 13: 313-8

Tormey CA, Hendrickson JE. 2019. Transfusion-related red blood cell alloantibodies: induction and consequences. *Blood, The Journal of the American Society of Hematology* 133: 1821-30

Trudell KS. 2005. Detection and identification of antibodies. *Modern blood banking and transfusion practices* 6: 216-40

White J. 2009. Pre-transfusion testing. *ISBT Science Series* 4: 37-44



## Lampiran

**Tabel Lampiran 1. Data Subjek Penelitian**

Pasien	JK	Variabel		Riwayat		Antibodi
		Golongan darah	Usia	Transfusi	Bukan transfusi	
1	pr	A	79		Bukan transfusi	anti-e
2	pr	A	64		Bukan transfusi	anti-E
3	pr	A	43		Bukan transfusi	anti-jka
4	lk	O	4		Bukan transfusi	anti-M
5	pr	B	38		Bukan transfusi	anti-M
6	pr	O	57		Bukan transfusi	anti-M
7	pr	B	56		Bukan transfusi	anti-lea
8	pr	B	28		Bukan transfusi	anti-lea
9	pr	B	30		Bukan transfusi	anti-E
10	pr	AB	30		Bukan transfusi	anti-lea
11	pr	O	7	Transfusi		anti-S
12	pr	B	50		Bukan transfusi	anti-jka
13	lk	O	41	Transfusi		anti-fyb
14	lk	B	64	Transfusi	Bukan transfusi	anti-lea
15	pr	O	64		Bukan transfusi	anti-lea
16	pr	B	50	Transfusi	Bukan transfusi	anti-lea
17	lk	O	59		Bukan transfusi	anti-P1
18	pr	AB	89		Bukan transfusi	anti-c
19	pr	O	40	Transfusi		anti-M
20	pr	A	56	Transfusi		anti-E
21	pr	A	31		Bukan transfusi	anti-E
22	pr	A	29		Bukan transfusi	anti-c
23	pr	A	43		Bukan transfusi	anti-P1
24	pr	O	48		Bukan transfusi	anti-M
25	pr	B	46	Transfusi		anti-E
26	pr	A	29		Bukan transfusi	anti-e
27	lk	O	53	Transfusi		anti-E
28	pr	AB	25	Transfusi		anti-jkb
29	pr	O	39	Transfusi		anti-jkb
30	lk	O	34	Transfusi		anti-kpa
31	pr	O	10	Transfusi		anti-E
32	lk	B	60		Bukan transfusi	anti-M
33	pr	B	48		Bukan transfusi	anti-E
34	lk	A	64	Transfusi		anti-fyb
35	pr	B	48		Bukan transfusi	anti-M
36	pr	O	27		Bukan transfusi	anti-lea
37	pr	O	53		Bukan transfusi	anti-E

Pasien	JK	Variabel		Riwayat		Antibodi
		Golongan darah	Usia	Transfusi	Bukan transfusi	
38	Pr	AB	47		Bukan transfusi	anti-E
39	LK	O	69	Transfusi		anti-C
40	LK	A	27		Bukan transfusi	anti-jka
41	PR	B	23		Bukan transfusi	anti-P1
42	pr	O	28	Transfusi		anti-lea
43	PR	O	30	Transfusi		anti-C
44	PR	B	76		Bukan transfusi	anti-jka
45	PR	A	40		Bukan transfusi	anti-E
46	PR	A	43	Transfusi		anti-c
47	pr	B	44	Transfusi		anti-lea
48	PR	B	42	Transfusi		anti-M
49	pr	A	28	Transfusi		anti-jka
50	pr	O	48	Transfusi		anti-lea
51	pr	B	23	Transfusi		anti-M
52	pr	B	30	Transfusi		anti-E
53	pr	B	16		Bukan transfusi	anti-e
54	pr	A	14	Transfusi		anti-S
55	pr	B	54	Transfusi		anti-Cw
56	PR	B	23	Transfusi		anti-M
57	pr	B	57	Transfusi		anti-E
58	pr	B	52	Transfusi		anti-E
59	pr	A	65	Transfusi		anti-E
60	pr	O	30	Transfusi		anti-lea
61	pr	A	35	Transfusi		anti-leb
62	pr	AB	47		Bukan transfusi	anti-E
63	PR	B	63	Transfusi		anti-leb
64	pr	O	46	Transfusi		anti-jka
65	LK	A	46	Transfusi		anti-E
66	LK	O	42		Bukan transfusi	anti-lea
67	PR	O	3		Bukan transfusi	anti-K
68	pr	B	1	Transfusi		anti-c
69	pr	AB	20	Transfusi		anti-E
70	pr	AB	28		Bukan transfusi	anti-lea
71	pr	B	68	Transfusi		anti-E
72	pr	A	55	Transfusi		anti-E
73	lk	A	65	Transfusi		anti-E
74	pr	A	29	Transfusi		anti-c
75	pr	B	48	Transfusi		anti-E
76	lk	O	62	Transfusi		anti-M
77	pr	A	64	Transfusi		anti-jka
78	pr	O	64		Bukan transfusi	anti-lea
79	lk	O	47	Transfusi		anti-fyb

Pasien	JK	Variabel		Riwayat		Antibodi
		Golongan darah	Usia	Transfusi	Bukan transfusi	
80	pr	A	67	Transfusi		anti-leb
81	pr	B	30		Bukan transfusi	anti-lea
82	pr	A	48		Bukan transfusi	anti-M
83	pr	O	53		Bukan transfusi	anti-E
84	pr	B	28		Bukan transfusi	anti-lea
85	lk	O	54		Bukan transfusi	anti-M
86	pr	O	7	Transfusi		anti-S
87	pr	O	61		Bukan transfusi	anti-leb
88	pr	A	20		Bukan transfusi	anti-K
89	pr	O	2		Bukan transfusi	anti-jkb
90	lk	O	44		Bukan transfusi	anti-p1
91	lk	B	64		Bukan transfusi	anti-p1
92	pr	A	35		Bukan transfusi	anti-jka
93	lk	A	17		Bukan transfusi	anti-leb
94	pr	O	43		Bukan transfusi	anti-E
95	pr	A	46		Bukan transfusi	anti-jka
96	pr	A	28		Bukan transfusi	anti-jka
97	lk	B	72		Bukan transfusi	anti-cw
98	pr	B	40		Bukan transfusi	anti-E
99	pr	O	42		Bukan transfusi	anti-p1
100	lk	B	53		Bukan transfusi	anti-M
101	pr	O	33		Bukan transfusi	anti-p1
102	lk	A	35		Bukan transfusi	anti-p1
103	lk	A	5		Bukan transfusi	anti-p1
104	pr	A	44		Bukan transfusi	anti-lea
105	pr	AB	39		Bukan transfusi	anti-C
106	pr	A	64		Bukan transfusi	anti-lea
107	pr	A	23		Bukan transfusi	anti- M
108	lk	B	64		Bukan transfusi	anti- M
109	lk	O	5		Bukan transfusi	anti- M
110	pr	O	30		Bukan transfusi	anti-e
111	pr	B	42		Bukan transfusi	anti-p1
112	pr	AB	46		Bukan transfusi	anti-leb
113	pr	A	21		Bukan transfusi	anti- M
114	lk	O	43		Bukan transfusi	anti-p1
115	pr	B	57		Bukan transfusi	anti-lea
116	pr	O	61		Bukan transfusi	anti-E
117	pr	O	54		Bukan transfusi	anti-jka
118	pr	B	55		Bukan transfusi	anti-c
119	pr	O	28		Bukan transfusi	anti-C
120	pr	AB	32		Bukan transfusi	anti-jka
121	pr	O	44		Bukan transfusi	anti-jka

Pasien	JK	Variabel		Riwayat		Antibodi
		Golongan darah	Usia	Transfusi	Bukan transfusi	
122	lk	A	76		Bukan transfusi	anti- M
123	pr	B	38		Bukan transfusi	anti-leb
124	lk	A	27		Bukan transfusi	anti- M
125	pr	B	43		Bukan transfusi	anti-E
126	pr	AB	22		Bukan transfusi	anti-E
127	pr	AB	3		Bukan transfusi	anti- M
128	lk	A	49		Bukan transfusi	anti-p1
129	pr	O	25		Bukan transfusi	anti-jkb
130	pr	B	30		Bukan transfusi	anti-E
131	lk	B	37		Bukan transfusi	anti-lea
132	lk	O	63		Bukan transfusi	anti-jka
133	pr	A	47		Bukan transfusi	anti-leb
134	pr	O	38		Bukan transfusi	anti-leb
135	pr	B	41		Bukan transfusi	anti-leb
136	pr	B	52		Bukan transfusi	anti-leb
137	pr	B	48		Bukan transfusi	anti-lea
138	pr	O	30		Bukan transfusi	anti-jka
139	Pr	A	27		Bukan transfusi	anti-p1
140	PR	A	66		Bukan transfusi	anti-p1
141	PR	B	44		Bukan transfusi	anti-p1
142	PR	AB	37		Bukan transfusi	anti-E
143	pr	B	36		Bukan transfusi	anti-leb
144	LK	O	43		Bukan transfusi	anti-c
145	LK	O	2		Bukan transfusi	anti-E
146	LK	A	5		Bukan transfusi	anti- M
147	PR	B	41		Bukan transfusi	anti-lea
148	pr	O	14		Bukan transfusi	anti-jka
149	PR	AB	32		Bukan transfusi	anti- M
150	pr	O	3		Bukan transfusi	anti- M
151	LK	B	60		Bukan transfusi	anti-leb
152	pr	B	1		Bukan transfusi	anti- M
153	pr	A	25		Bukan transfusi	anti-leb
154	LK	O	48		Bukan transfusi	anti-E



**Tabel Lampiran 2. Cara Kerja Pemeriksaan**

<p>Persiapan sampel</p>	<p>Volume sampel Dewasa: EDTA 5-10 ml dan BEKU 5-10 ml, Bayi: EDTA 3-5 ml dan BEKU 3-5 ml sertakan sampel darah ibu EDTA 3 ml, Sampel dicentrifugasi 3000 rpm selama 2 menit.</p>
<p>Skrining</p>	<p>Metoda Tabung.</p> <ol style="list-style-type: none"> <li>1. Menyiapkan tiga tabung, Tabung S1: sel panel kecil S1, Tabung S2: sel panel kecil S2, Tabung AK: Suspensi sel darah merah pasien 5% dalam NaCl 0,9.</li> <li>2. Menginkubasi pada suhu 20°C selama 60 menit.</li> <li>3. Melakukan pemutaran pada 3000 rpm pada centrifuge tabung selama 15 detik, baca hasil.</li> <li>4. Menambahkan 2 tetes Bouvine Albumin 22% kesetiap tabung.</li> <li>5. Menginkubasi pada suhu 37°C di <i>ID-Incubator</i> selama 15 menit.</li> <li>6. Melakukan pemutaran pada 3000rpm di Centrifuge tabung selama 15 detik, baca hasil.</li> <li>7. Melakukan pencucian dengan NaCl 0,9% sebanyak 3 kali.</li> <li>8. Menambahkan 2 tetes coombs serum kesetiap tabung.</li> <li>9. Melakukan pemutaran pada 3000 rpm di centrifuge tabung selama 15 detik.</li> <li>10. Membaca hasil secara makroskopis.</li> </ol> <p>Metode Gel</p> <ol style="list-style-type: none"> <li>1. Menyiapkan 3 lubang pada Liss card, beri identitas S1, S2, AK.</li> <li>2. Memasukkan :50 µL sel panel kecil S1 kedalam lubang S1. 50 µL sel panel kecil S2 kedalam lubang S2 50 µL suspensi sel darah merah pasien 1% dalam diluent kedalam lubang AK.</li> <li>3. Memasukkan 25 µL serum pasien kesetiap lubang.</li> <li>4. Meinkubasi pada suhu 37°C di <i>ID-Incubator</i> selama 15 menit.</li> <li>5. Melakukan pemutaran dengan ID-centrifuge selama 10 menit. Baca hasil dan Lakukan <b>second personal check</b> pada hasil pemeriksaan antibodi pasien.</li> </ol>
<p>Identifikasi</p>	<p>Metode Tabung</p> <ol style="list-style-type: none"> <li>1. Menyiapkan 12 tabung, memberi identitas 1-11 dan AK.</li> <li>2. Meneteskan masing – masing tabung 2 tetes serum/plasma pasien.</li> <li>3. Menambahkan 1 Tetes kepada masing-masing tabung: Sel panel besar S1 kedalam tabung 1, Sel panel besar S2 kedalam tabung 2, Sel panel besar S3 kedalam tabung 3, Sel panel besar S4 kedalam tabung 4, Sel panel besar S5 kedalam tabung 5, Sel panel besar S6 kedalam tabung 6, Sel panel besar S7 kedalam tabung 7, Sel panel besar S8 kedalam</li> </ol>

	<p>tabung 8, Sel panel besar S9 kedalam tabung 9, Sel panel besar S10 kedalam tabung 10. Sel panel besar S11 kedalam tabung 11, dan Suspensi sel darah merah pasien 5% dalam NaCl 0,9% kedalam tabung AK (tabung 12).</p> <ol style="list-style-type: none"> <li>4. Meinkubasi pada suhu 20°C selama 60 menit.</li> <li>5. Melakukan pemutaran 3000 rpm pada centrifuge tabung selama 15 detik, Baca hasil.</li> <li>6. Menambahkan 2 tetes Bouvine Albumin 22% kesetiap tabung.</li> <li>7. Meinkubasi pada suhu 37°C di <i>ID-Incubator</i> selama 15 menit.</li> <li>8. Melakukan pemutaran 3000 rpm di centrifuge tabung selama 15 detik, Baca hasil.</li> <li>9. Melakukan pencucian dengan NaCl 0,9% sebanyak 3x.</li> <li>10. Menambahkan 2 tetes coombs serum kesetiap tabung.</li> <li>11. Melakukan pemutaran 3000 rpm di centrifuge tabung selama 15 detik.</li> <li>12. Membaca hasil secara makroskopis.</li> </ol> <p>Metode gel</p> <ol style="list-style-type: none"> <li>1. Menyiapkan 12 lubang pada <i>Liss card</i>, mem beri identitas 1-11 dan AK.</li> <li>2. Memasukkan 50 µL kedalam masing-masing tabung: Sel panel besar S1 kedalam lubang 1, Sel panel besar S2 kedalam lubang 2, Sel panel besar S3 kedalam lubang 3, Sel panel besar S4 kedalam lubang 4, Sel panel besar S5 kedalam lubang 5, Sel panel besar S6 kedalam lubang 6, Sel panel besar S7 kedalam lubang 7, Sel panel besar S8 kedalam lubang 8, Sel panel besar S9 kedalam lubang 9, Sel panel besar S10 kedalam lubang 10, Sel panel besar, S11 kedalam lubang 11 dan Suspense sel darah merah pasien 1% dalam diluents kedalam lubang AK (lubang 12).</li> <li>3. Memasukkan 25 µL serum pasien kesetiap lubang.</li> <li>4. Meinkubasi pada suhu 37°C di <i>ID-Incubator</i> selama 15 menit.</li> <li>5. Melakukan pemutaran dengan <i>ID-centrifuge</i> selama 10 menit.</li> <li>6. Membaca hasil.</li> </ol>
<p>Hasil</p>	<p>Skrining antibodi dengan hasil positif pada S1 atau S2, maka lanjutkan dengan identifikasi antibodi untuk menentukan jenis antibodi yang spsesifik. Identifikasi antibodi dengan hasil yang didapat selanjutnya dicocokkan dengan antigram atau daftar antibodi yang terdapat pada kit reagen.</p>

Tabel Lampiran 3. Uji Korelasi Riwayat Transfusi

**Antibody \* Riwayat Crosstabulation**

		Riwayat			
		BELUM PERNAH TRANSFUSI	SUDAH PERNAH TRANSFUSI	Total	
Antibody	anti-E	Count	18 <sub>a</sub>	14 <sub>a</sub>	32
		% within Antibody	56.3%	43.8%	100.0%
	anti-e	Count	4 <sub>a</sub>	0 <sub>a</sub>	4
		% within Antibody	100.0%	0.0%	100.0%
	anti-c	Count	4 <sub>a</sub>	3 <sub>a</sub>	7
		% within Antibody	57.1%	42.9%	100.0%
	anti-C	Count	2 <sub>a</sub>	2 <sub>a</sub>	4
		% within Antibody	50.0%	50.0%	100.0%
	anti-Cw	Count	1 <sub>a</sub>	1 <sub>a</sub>	2
		% within Antibody	50.0%	50.0%	100.0%
	anti-Jka	Count	13 <sub>a</sub>	3 <sub>a</sub>	16
		% within Antibody	81.3%	18.8%	100.0%
	Anti-Jkb	Count	2 <sub>a</sub>	2 <sub>a</sub>	4
		% within Antibody	50.0%	50.0%	100.0%
	anti-Fyb	Count	0 <sub>a</sub>	3 <sub>b</sub>	3
		% within Antibody	0.0%	100.0%	100.0%
	Anti-Kpa	Count	0 <sub>a</sub>	1 <sub>a</sub>	1
		% within Antibody	0.0%	100.0%	100.0%
	anti-Lea	Count	16 <sub>a</sub>	6 <sub>a</sub>	22
		% within Antibody	72.7%	27.3%	100.0%
	anti Leb	Count	11 <sub>a</sub>	3 <sub>a</sub>	14
		% within Antibody	78.6%	21.4%	100.0%
	anti-M	Count	20 <sub>a</sub>	5 <sub>a</sub>	25
		% within Antibody	80.0%	20.0%	100.0%
	anti P1	Count	15 <sub>a</sub>	0 <sub>b</sub>	15
		% within Antibody	100.0%	0.0%	100.0%
	anti-S	Count	0 <sub>a</sub>	3 <sub>b</sub>	3
		% within Antibody	0.0%	100.0%	100.0%
	anti-K	Count	2 <sub>a</sub>	0 <sub>a</sub>	2
		% within Antibody	100.0%	0.0%	100.0%
Total		Count	108	46	154
		% within Antibody	70.1%	29.9%	100.0%

Each subscript letter denotes a subset of Riwayat categories whose column proportions do not differ significantly from each other at the .05 level.

**Chi-Square Tests**

	Value	df	Asymptotic Significance (2- sided)
Pearson Chi-Square	33.474 <sup>a</sup>	14	.002
Likelihood Ratio	39.730	14	.000
Linear-by-Linear Association	4.950	1	.026
N of Valid Cases	154		

a. 21 cells (70.0%) have expected count less than 5. The minimum expected count is .30.

Tabel Lampiran 4. Uji Korelasi Jenis Kelamin

Uji korelasi jenis kelamin

**Antibody \* JK Crosstabulation**

Antibody		JK		Total
		laki-laki	Perempuan	
anti-E	Count	5 <sub>a</sub>	27 <sub>a</sub>	32
	% within Antibody	15.6%	84.4%	100.0%
anti-e	Count	0 <sub>a</sub>	4 <sub>a</sub>	4
	% within Antibody	0.0%	100.0%	100.0%
anti-c	Count	1 <sub>a</sub>	6 <sub>a</sub>	7
	% within Antibody	14.3%	85.7%	100.0%
anti-C	Count	1 <sub>a</sub>	3 <sub>a</sub>	4
	% within Antibody	25.0%	75.0%	100.0%
anti-Cw	Count	1 <sub>a</sub>	1 <sub>a</sub>	2
	% within Antibody	50.0%	50.0%	100.0%
anti-Jka	Count	2 <sub>a</sub>	14 <sub>a</sub>	16
	% within Antibody	12.5%	87.5%	100.0%
Anti-Jkb	Count	0 <sub>a</sub>	4 <sub>a</sub>	4
	% within Antibody	0.0%	100.0%	100.0%
anti-Fyb	Count	3 <sub>a</sub>	0 <sub>b</sub>	3
	% within Antibody	100.0%	0.0%	100.0%
Anti-Kpa	Count	1 <sub>a</sub>	0 <sub>a</sub>	1
	% within Antibody	100.0%	0.0%	100.0%
anti-Lea	Count	3 <sub>a</sub>	19 <sub>a</sub>	22
	% within Antibody	13.6%	86.4%	100.0%
anti Leb	Count	2 <sub>a</sub>	12 <sub>a</sub>	14
	% within Antibody	14.3%	85.7%	100.0%
anti-M	Count	10 <sub>a</sub>	15 <sub>b</sub>	25
	% within Antibody	40.0%	60.0%	100.0%
anti P1	Count	7 <sub>a</sub>	8 <sub>b</sub>	15
	% within Antibody	46.7%	53.3%	100.0%
anti-S	Count	0 <sub>b</sub>	3 <sub>a</sub>	3
	% within Antibody	0.0%	100.0%	100.0%
anti-K	Count	0 <sub>a</sub>	2 <sub>a</sub>	2
	% within Antibody	0.0%	100.0%	100.0%
Total	Count	36	118	154
	% within Antibody	23.4%	76.6%	100.0%

Each subscript letter denotes a subset of JK categories whose column proportions do not differ significantly from each other at the .05 level.

**Chi-Square Tests**

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	30.538 <sup>a</sup>	14	.006
Likelihood Ratio	31.292	14	.005
Linear-by-Linear Association	3.968	1	.046
N of Valid Cases	154		

a. 20 cells (66.7%) have expected count less than 5. The minimum expected count is .23.

Tabel Lampiran 5. Uji Korelasi Golongan Darah

			Goloda				
			A	B	O	AB	Total
Antibody	anti-E	Count	8 <sub>a</sub>	11 <sub>a</sub>	8 <sub>a</sub>	5 <sub>a</sub>	32
		% within Antibody	25.0%	34.4%	25.0%	15.6%	100.0%
anti-e	Count	2 <sub>a</sub>	1 <sub>a</sub>	1 <sub>a</sub>	0 <sub>a</sub>	4	
		% within Antibody	50.0%	25.0%	25.0%	0.0%	100.0%
anti-c	Count	3 <sub>a</sub>	2 <sub>a</sub>	1 <sub>a</sub>	1 <sub>a</sub>	7	
		% within Antibody	42.9%	28.6%	14.3%	14.3%	100.0%
anti-C	Count	0 <sub>a</sub>	0 <sub>a</sub>	3 <sub>a</sub>	1 <sub>a</sub>	4	
		% within Antibody	0.0%	0.0%	75.0%	25.0%	100.0%
anti-Cw	Count	0 <sub>a</sub>	2 <sub>a</sub>	0 <sub>a</sub>	0 <sub>a</sub>	2	
		% within Antibody	0.0%	100.0%	0.0%	0.0%	100.0%
anti-Jka	Count	7 <sub>a</sub>	2 <sub>a</sub>	6 <sub>a</sub>	1 <sub>a</sub>	16	
		% within Antibody	43.8%	12.5%	37.5%	6.3%	100.0%
Anti-Jkb	Count	0 <sub>a</sub>	0 <sub>a</sub>	3 <sub>a</sub>	1 <sub>a</sub>	4	
		% within Antibody	0.0%	0.0%	75.0%	25.0%	100.0%
anti-Fyb	Count	1 <sub>a</sub>	0 <sub>a</sub>	2 <sub>a</sub>	0 <sub>a</sub>	3	
		% within Antibody	33.3%	0.0%	66.7%	0.0%	100.0%
Anti-Kpa	Count	0 <sub>a</sub>	0 <sub>a</sub>	1 <sub>a</sub>	0 <sub>a</sub>	1	
		% within Antibody	0.0%	0.0%	100.0%	0.0%	100.0%
anti-Lea	Count	2 <sub>a</sub>	11 <sub>a</sub>	7 <sub>a</sub>	2 <sub>a</sub>	22	
		% within Antibody	9.1%	50.0%	31.8%	9.1%	100.0%
anti Leb	Count	5 <sub>a</sub>	6 <sub>a</sub>	2 <sub>a</sub>	1 <sub>a</sub>	14	
		% within Antibody	35.7%	42.9%	14.3%	7.1%	100.0%
anti-M	Count	6 <sub>a</sub>	9 <sub>a</sub>	8 <sub>a</sub>	2 <sub>a</sub>	25	
		% within Antibody	24.0%	36.0%	32.0%	8.0%	100.0%
anti P1	Count	6 <sub>a</sub>	4 <sub>a</sub>	5 <sub>a</sub>	0 <sub>a</sub>	15	
		% within Antibody	40.0%	26.7%	33.3%	0.0%	100.0%
anti-S	Count	1 <sub>a</sub>	0 <sub>a</sub>	2 <sub>a</sub>	0 <sub>a</sub>	3	
		% within Antibody	33.3%	0.0%	66.7%	0.0%	100.0%
anti-K	Count	1 <sub>a</sub>	0 <sub>a</sub>	1 <sub>a</sub>	0 <sub>a</sub>	2	
		% within Antibody	50.0%	0.0%	50.0%	0.0%	100.0%
Total	Count	42	48	50	14	154	
	% within Antibody	27.3%	31.2%	32.5%	9.1%	100.0%	

Each subscript letter denotes a subset of Goloda categories whose column proportions do not differ significantly from each other at the .05 level.

Chi-Square Tests			Asymptotic
Value	df		Significance (2-sided)
Pearson Chi-Square	42.864 <sup>a</sup>	42	.434
Likelihood Ratio	51.064	42	.159
Linear-by-Linear Association	.518	1	.472
N of Valid Cases	154		

a. 50 cells (83.3%) have expected count less than 5. The minimum expected count is .09.

Tabel Lampiran 6. Uji Korelasi Usia

**Antibody \* usia Crosstabulation**

		usia							
		0-5	6-11	12-25	26-45	46-65	6.00	Total	
Antibody	anti-E	Count	1 <sub>a</sub>	1 <sub>a</sub>	2 <sub>a</sub>	8 <sub>a</sub>	19 <sub>a</sub>	1 <sub>a</sub>	32
	% within Antibody	3.1%	3.1%	6.3%	25.0%	59.4%	3.1%	100.0%	
	anti-e	Count	0 <sub>a</sub>	0 <sub>a</sub>	1 <sub>a</sub>	2 <sub>a</sub>	0 <sub>a</sub>	1 <sub>a</sub>	4
	% within Antibody	0.0%	0.0%	25.0%	50.0%	0.0%	25.0%	100.0%	
	anti-c	Count	1 <sub>a</sub>	0 <sub>a</sub>	0 <sub>a</sub>	4 <sub>a</sub>	1 <sub>a</sub>	1 <sub>a</sub>	7
	% within Antibody	14.3%	0.0%	0.0%	57.1%	14.3%	14.3%	100.0%	
	anti-C	Count	0 <sub>a</sub>	0 <sub>a</sub>	0 <sub>a</sub>	3 <sub>a</sub>	0 <sub>a</sub>	1 <sub>a</sub>	4
	% within Antibody	0.0%	0.0%	0.0%	75.0%	0.0%	25.0%	100.0%	
	anti-C <sub>0</sub>	Count	0 <sub>a</sub>	0 <sub>a</sub>	0 <sub>a</sub>	0 <sub>a</sub>	1 <sub>a</sub>	1 <sub>a</sub>	2
	% within Antibody	0.0%	0.0%	0.0%	0.0%	50.0%	50.0%	100.0%	
	anti-Jka	Count	0 <sub>a</sub>	0 <sub>a</sub>	1 <sub>a</sub>	8 <sub>a</sub>	6 <sub>a</sub>	1 <sub>a</sub>	16
	% within Antibody	0.0%	0.0%	6.3%	50.0%	37.5%	6.3%	100.0%	
	Anti-Jk <sub>b</sub>	Count	1 <sub>a</sub>	0 <sub>a</sub>	2 <sub>a</sub>	1 <sub>a</sub>	0 <sub>a</sub>	0 <sub>a</sub>	4
	% within Antibody	25.0%	0.0%	50.0%	25.0%	0.0%	0.0%	100.0%	
	anti-Ex <sub>b</sub>	Count	0 <sub>a</sub>	0 <sub>a</sub>	0 <sub>a</sub>	1 <sub>a</sub>	2 <sub>a</sub>	0 <sub>a</sub>	3
	% within Antibody	0.0%	0.0%	0.0%	33.3%	66.7%	0.0%	100.0%	
	Anti-Kpa	Count	0 <sub>a</sub>	0 <sub>a</sub>	0 <sub>a</sub>	1 <sub>a</sub>	0 <sub>a</sub>	0 <sub>a</sub>	1
	% within Antibody	0.0%	0.0%	0.0%	100.0%	0.0%	0.0%	100.0%	
	anti-Lea	Count	0 <sub>a</sub>	0 <sub>a</sub>	0 <sub>a</sub>	13 <sub>a</sub>	9 <sub>a</sub>	0 <sub>a</sub>	22
	% within Antibody	0.0%	0.0%	0.0%	59.1%	40.9%	0.0%	100.0%	
	anti Leb	Count	0 <sub>a</sub>	0 <sub>a</sub>	1 <sub>a</sub>	6 <sub>a</sub>	6 <sub>a</sub>	1 <sub>a</sub>	14
	% within Antibody	0.0%	0.0%	7.1%	42.9%	42.9%	7.1%	100.0%	
	anti-M	Count	6 <sub>a</sub>	0 <sub>a, b</sub>	4 <sub>a, b</sub>	5 <sub>b</sub>	9 <sub>a, b</sub>	1 <sub>a, b</sub>	25
	% within Antibody	24.0%	0.0%	16.0%	20.0%	36.0%	4.0%	100.0%	
	anti P1	Count	1 <sub>a</sub>	0 <sub>a</sub>	1 <sub>a</sub>	8 <sub>a</sub>	4 <sub>a</sub>	1 <sub>a</sub>	15
	% within Antibody	6.7%	0.0%	6.7%	53.3%	26.7%	6.7%	100.0%	
	anti-S	Count	0 <sub>a, b</sub>	1 <sub>a</sub>	1 <sub>a, b</sub>	0 <sub>a</sub>	1 <sub>a</sub>	0 <sub>a, b</sub>	3
	% within Antibody	0.0%	33.3%	33.3%	0.0%	33.3%	0.0%	100.0%	
	anti-K	Count	1 <sub>a</sub>	0 <sub>a</sub>	1 <sub>a</sub>	0 <sub>a</sub>	0 <sub>a</sub>	0 <sub>a</sub>	2
	% within Antibody	50.0%	0.0%	50.0%	0.0%	0.0%	0.0%	100.0%	
Total	Count	11	2	14	60	58	9	154	
	% within Antibody	7.1%	1.3%	9.1%	39.0%	37.7%	5.8%	100.0%	

Each subscript letter denotes a subset of **usia** categories whose column proportions do not differ significantly from each other at the .05 level.

Antibody * usia	154	100.0%	0	0.0%	154	100.0%
-----------------	-----	--------	---	------	-----	--------

**Chi-Square Tests**

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	109.454 <sup>a</sup>	70	.002
Likelihood Ratio	88.764	70	.064
Linear-by-Linear Association	5.581	1	.018
N of Valid Cases	154		

a. 78 cells (86.7%) have expected count less than 5. The minimum expected count is .01.

## Lampiran 7. Permohonan Ijin Pengambilan Data



### UNIVERSITAS NASIONAL FAKULTAS BIOLOGI DAN PERTANIAN

Program Studi Biologi Akreditasi Unggul  
Program Studi Agroteknologi Akreditasi B  
Program Studi Magister Biologi Akreditasi Baik Sekali

Jl. Sawo Manis No.61, Pasar Minggu, Jakarta Selatan 12520 Telp/Fax. 021.78833384 Homepage : <http://www.unas.ac.id>  
E-mail : [s1biologi@cvitas.unas.ac.id](mailto:s1biologi@cvitas.unas.ac.id), [fabions2020@gmail.com](mailto:fabions2020@gmail.com), [fpertaunas85@gmail.com](mailto:fpertaunas85@gmail.com), [s2biologi@cvitas.unas.ac.id](mailto:s2biologi@cvitas.unas.ac.id)

Nomor : 976/DEK/FBP-PB/1.1b/XI/2023  
Hal : Permohonan Izin Penelitian

Kepada Yth:  
Direktur UTD PMI  
Kab. Bekasi

Ditempat

Dengan Hormat,

Bersama ini kami sampaikan bahwa untuk memenuhi salah satu syarat guna mendapatkan gelar sarjana (S1) pada prodi Biologi Fakultas Biologi dan Pertanian Universitas Nasional Jakarta, setiap mahasiswa diwajibkan untuk melakukan penelitian dalam rangka penulisan Skripsi Sarjana (S1). Sehubungan dengan hal tersebut diatas, bersama ini kami mohon bantuan Bapak/Ibu untuk dapat mengizinkan mahasiswa kami tersebut di bawah ini :

Nama : Rawina  
Nomor Pokok : 206201446058  
Tempat/Tgl. Lahir : Tj Air, 4 maret 1974  
Alamat : Metland Tambun Cluster Fontania Blok n3/ 10  
Bekasi, Jawa Barat

Untuk dapat melakukan Penelitian dengan judul : "*Hubungan Antibodi Irreguler terhadap Riwayat Transfusi Berdasarkan Jenis Kelamin, Golongan Darah dan Usia di UTD PMI Kabupaten Bekasi.*" Selanjutnya mengenai peraturan dan ketentuan yang berlaku yang harus ditaati oleh mahasiswa, dalam hal ini sepenuhnya kami serahkan pada kebijaksanaan instansi terkait.

Demikian kami sampaikan dan atas perhatian serta kebijakan yang diberikan, kami ucapkan terima kasih.

Jakarta, 27 November 2023



Dr. Tatang Mitra Setia, M.Si

## Lampiran 8. Balasan Surat Ijin Pengambilan Data

 **PALANG  
MERAH  
INDONESIA**

Bekasi, 15 Desember 2023

Nomor : 012/UTD-ADM/XII/2023  
Lampiran : -  
Perihal : *Permohonan Izin Penelitian*

Kepada Yth.  
Dekan Universitas Nasional Fakultas Biologi dan Pertanian  
Di -  
Tempat

Menjawab dan menindaklanjuti Surat Dekan Universitas Nasional Fakultas Biologi dan Pertanian nomor: 976/DEK/FBP-PB/1.1b/XI/2023 tanggal 27 November 2023 perihal tersebut di atas, maka dapat kami sampaikan bahwa kami memberikan izin penelitian kepada :

Nama : Rawina  
NIM : 206201446058  
Judul KTI : "Hubungan Antibodi Irreguler terhadap Riwayat Transfusi Berdasarkan Jenis Kelamin, Golongan Darah dan Usia di UTD PMI Kabupaten Bekasi."  
Lokasi : Unit Transfusi Darah Palang Merah Indonesia Kabupaten Bekasi

Demikian kami sampaikan, atas perhatian dan kerjasamanya kami ucapkan terima kasih.

Unit Transfusi Darah  
PALANG MERAH INDONESIA  
Kabupaten Bekasi  
Kepala,


dr. Dewi Kusuma Astuti, M.Biomed  
NPP. 1982 2410 2021 136

Tembusan :

**UNIVERSITAS NASIONAL**




● 25% Overall Similarity

Top sources found in the following databases:

- 22% Internet database
- 15% Publications database
- Crossref database
- Crossref Posted Content database
- 16% Submitted Works database

TOP SOURCES

The sources with the highest number of matches within the submission. Overlapping sources will not be displayed.



1	<b>scribd.com</b> Internet	1%
2	<b>lp2m.stikesayani.ac.id</b> Internet	<1%
3	<b>repository.poltekkes-tjk.ac.id</b> Internet	<1%
4	<b>researchgate.net</b> Internet	<1%
5	<b>journal.umpr.ac.id</b> Internet	<1%
6	<b>De Montfort University on 2023-05-10</b> Submitted works	<1%
7	<b>perpustakaan.poltekkes-malang.ac.id</b> Internet	<1%
8	<b>Middlesex University on 2023-03-26</b> Submitted works	<1%

9	Universitas Muhammadiyah Surakarta on 2014-02-04 Submitted works	<1%
10	jurnal.fk.umi.ac.id Internet	<1%
11	Universitas Nasional on 2020-10-06 Submitted works	<1%
12	id.scribd.com Internet	<1%
13	prr.hec.gov.pk Internet	<1%
14	journals.plos.org Internet	<1%
15	publikationen.sulb.uni-saarland.de Internet	<1%
16	docplayer.info Internet	<1%
17	scholar.unand.ac.id Internet	<1%
18	tessera.spandidos-publications.com Internet	<1%
19	journal.umpalangkaraya.ac.id Internet	<1%



t

<1%

20

London Metropolitan University on 2023-06-17

Submitted works

<1%



21	RMIT University on 2015-10-18 Submitted works	<1%
22	jlupub.ub.uni-giessen.de Internet	<1%
23	m.amedeo.com Internet	<1%
24	repository.unjaya.ac.id Internet	<1%
25	cibtech.org Internet	<1%
26	CTI Education Group on 2023-07-01 Submitted works	<1%
27	dspace.alquds.edu Internet	<1%
28	iji.sums.ac.ir Internet	<1%
29	lppm.unjani.ac.id Internet	<1%
30	openaccess.leidenuniv.nl Internet	<1%
31	longdom.org	Interne



t

<1%

32

123dok.com

Internet

<1%



33	Mourad, Z., H. Hassab, D. Younan, and A. Abdo. "Human leucocyte anti... Crossref	<1%
34	RMIT University on 2021-03-21 Submitted works	<1%
35	Riga Stradins University on 2020-07-13 Submitted works	<1%
36	haematology.kk.usm.my Internet	<1%
37	Shaona Wang, Jiaohua Wang, Xiaomei Mo, Zhen Wang, Yubin Wu, Feng... Crossref	<1%
38	"Transfusion Transmittable Infections", Vox Sanguinis, 11/2007 Crossref	<1%
39	idoc.pub Internet	<1%
40	University of Dammam on 2023-04-13 Submitted works	<1%
41	repo.bunghatta.ac.id Internet	<1%
42	text-id.123dok.com Internet	<1%
43	uia.e-journal.id	Interne



t

<1%

44

acta.tums.ac.ir

Internet

<1%



45	jurnal.ensiklopediaku.org	Internet	<1%
46	prin.or.id	Internet	<1%
47	jcdr.net	Internet	<1%
48	Norma Farizah Fahmi, Dwi Aprilia Anggraini, Yogi Khoirul Abror. "POLA ...	Crossref	<1%
49	jurnal.usk.ac.id	Internet	<1%
50	grafiati.com	Internet	<1%
51	Galway Mayo Institute of Technology (GMIT) on 2023-12-18	Submitted works	<1%
52	Napier University on 2023-03-28	Submitted works	<1%
53	mdpi.com	Internet	<1%
54	lib.ui.ac.id	Internet	<1%
55	guvenplus.com.tr	Internet	<1%





t

<1%

56

Universitas Nasional on 2020-10-05

<1%

Submitted works



57	eprints.uwe.ac.uk Internet	<1%
58	Napier University on 2012-05-25 Submitted works	<1%
59	acikerisim.deu.edu.tr Internet	<1%
60	Konsorsium Perguruan Tinggi Swasta Indonesia II on 2023-12-18 Submitted works	<1%
61	core.ac.uk Internet	<1%
62	repository.unair.ac.id Internet	<1%
63	Arwa Z. Al-Riyami, Shahina Daar. "Red cell alloimmunization in transfu... Crossref	<1%
64	Nur Azzahra Baiti Dewi, Ganjar Noviar, Adang Durachim, Nina Marlina.... Crossref	<1%
65	Dwi Eni Danarsih, Dyah Artini, Nur'Aini Purnamaningsih. "OBESITY SCR... Crossref	<1%
66	Universitas Muhammadiyah Surakarta on 2014-11-01 Submitted works	<1%
67	Wilfried H. Purba, Tri Yunis Miko Wahyono, Akira Ito, Widarso H. S. Wid...	



rossref

<1%

68

docobook.com

Internet

<1%



69	lib.ibs.ac.id	Internet	<1%
70	repository2.unw.ac.id	Internet	<1%
71	vdokumen.com	Internet	<1%
72	Badan PPSDM Kesehatan Kementerian Kesehatan on 2023-07-29	Submitted works	<1%
73	Dewi Nur Anggraeni. "Gambaran Pengetahuan Golongan Darah Untuk ...	Crossref	<1%
74	Macquarie University on 2023-10-28	Submitted works	<1%
75	Nur'Aini Purnamaningsih, Siti Fajriati Djirimu, Francisca Romana Sri Su...	Crossref	<1%
76	RMIT University on 2020-09-03	Submitted works	<1%
77	Sriwijaya University on 2020-01-06	Submitted works	<1%
78	Sriwijaya University on 2021-08-12	Submitted works	<1%
79	Unika Soegijapranata on 2015-11-27		Submit

ted works

<1%

80

Yogi Abror. "PEMERIKSAAN GOLONGAN DARAH ABO MENGGUNAKAN...

<1%

Crossref



81	doaj.org Internet	<1%
82	etheses.uin-malang.ac.id Internet	<1%
83	id.123dok.com Internet	<1%
84	journal.ummat.ac.id Internet	<1%
85	ojs.unm.ac.id Internet	<1%
86	peraturan.bpk.go.id Internet	<1%
87	repo.poltekkes-medan.ac.id Internet	<1%
88	infolabmed.com Internet	<1%
89	neliti.com Internet	<1%

